"The voice for cancer physicians and their patients in Massachusetts."

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 08 Jan 2020 2:47 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved pembrolizumab (Keytruda; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. Read full press release.

  • 07 Jan 2020 1:24 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved olaparib (Lynparza; AstraZeneca) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma, as detected by an FDA-approved test, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Read full press release

  • 07 Jan 2020 1:19 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu; Daiichi Sankyo) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Read full press release

  • 19 Dec 2019 1:49 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev; Astellas) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting. Read full press release.

  • 17 Dec 2019 8:19 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved enzalutamide (Xtandi; Astellas) for patients with metastatic castration-sensitive prostate cancer (mCSPC). Read full press release.

  • 05 Dec 2019 2:14 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved atezolizumab (Tecentriq; Genentech) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. Read full press release

  • 21 Nov 2019 2:57 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved acalabrutinib (Calquence; AstraZeneca) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release

  • 18 Nov 2019 8:54 AM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved crizanlizumab-tmca (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. Read full press release

  • 15 Nov 2019 2:24 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa; BeiGene) for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Read full press release.

  • 08 Nov 2019 2:21 PM | Nathan Strunk (Administrator)

    The U.S. Food and Drug Administration approved luspatercept-aamt (Reblozyl; Celgene) for treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions. Read full press release

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

Upcoming events

  • No upcoming events

Massachusetts Society of Clinical Oncologists (c)

P.O. Box 549154, Waltham, MA, 02454
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software